Open Orphan to begin first-ever COVID-19 challenge trial
May 6, 2022Medical Communications
Open Orphan has been appointed by an unnamed existing “big pharma” client to host a Phase II field study of …
FDA narrows use of J&J vaccine due to blood clot risk
May 6, 2022Medical Communications
The FDA has limited the use of Johnson & Johnson’s coronavirus vaccine, to adults who cannot, or refuse to get, …
AstraZeneca’s heart disease drug meets key endpoints in Phase III
May 6, 2022Medical Communications
AstraZeneca’s treatment for heart disease has delivered positive high-level results from its Phase III DELIVER trial.Farxiga (dapagliflozin) is already approved …
First regenerative cell therapy for hearing loss
May 5, 2022Business Services
Rinri Therapeutics have announced the MHRA has awarded an innovation passport to the company’s lead candidate, Rincell-1. Rincell-1 is a …
Nearly three million people receive lifesaving NHS cancer checks
May 5, 2022Business Services
A record three million people received vital NHS cancer tests from March 2021 to February 2022, compared to 2.4 million …
Health experts report more symptoms of long COVID-19
May 5, 2022Business Services
According to health experts, many COVID-19 patients are still suffering the effects of the condition months after they first started …
FDA approval for first in vitro diagnostic for early Alzheimer’s detection
May 5, 2022Business Services
The US FDA has approved the first in vitro diagnostic to aid in the early detection of Alzheimer’s disease (AD). …
BLINCYTO approved in China for leukaemia treatment
May 4, 2022Research and Development
The China National Medical Products Administration (NMPA) has granted conditional approval of BLINCYTO (blinatumomab), as an injection for the treatment …
Amphista Therapeutics and Bristol Myers Squibb partner for development of protein degradation therapeutics
May 4, 2022Research and Development
Amphista and Bristol-Myers Squibb have announced a strategic collaboration and license agreement.Under the terms of the collaboration, BMS and Amphista …
Smartphone app could screen for Alzheimer’s disease
May 4, 2022Research and Development
Researchers at the University of California San Diego have developed a smartphone app with the potential to screen for Alzheimer’s …
WHO announce upcoming updates on treatment of drug-resistant tuberculosis
May 4, 2022Research and Development
A rapid communication released by WHO Global Tuberculosis Programme has announced upcoming updates to the guidance on the treatment of …
Jyseleca recommended by HSE for treatment of ulcerative colitis in Ireland
May 3, 2022Manufacturing and Production
Galapagos Biotech LTD has announced that further to approval from the Health Service Executive (HSE), eligible patients in Ireland will …
EU plans to cut unneeded medical tests with data health plan
May 3, 2022Manufacturing and Production
The EC has announced plans to make health data easier to access for patients, medics, regulators, and researchers, to improve …
FDA approve first nonstimulant ADHD med for adults in two decades
May 3, 2022Manufacturing and Production
The FDA has expanded the indication of Supernus’s Qelbree to patients aged 18 and older, marking the drug as the …
EC approves Cabotemyx as second-line treatment for thyroid cancer patients
May 3, 2022Manufacturing and Production
The EC has approved the use of Cabotemyx (cabozantinib) as a monotherapy for the treatment of adult patients with locally …
Discharging untested patients to care homes was ‘unlawful’, says high court ruling
April 29, 2022Medical Communications
The High Court has ruled that government policies on discharging untested patients from hospital to care homes in England, at …
Pfizer DMD trial moves forward after FDA lifts hold
April 29, 2022Medical Communications
Pfizer has announced that it will open the first ever US sites in its Phase III trial study, evaluating its …
FDA approval for first drug to treat inherited heart condition
April 29, 2022Medical Communications
Bristol Myers Squibb has received approval from the FDA for their drug, Camzyos™ (mavacamten), marking the drug as the first …
OMass Therapeutics raises $100 million to progress immunology and rare diseases drug pipeline
April 28, 2022Business Services
OMass Therapeutics have announced the $100 million (£75.5 million) Series B financing to progress its drug pipeline in immunology and …
NOCIRA announces breakthrough device designation by FDA for migraine treatment
April 28, 2022Business Services
NOCIRA is the first company to announce the FDA’s Breakthrough Device designation for the treatment of migraine attacks in both …
Latest content
